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Summary
We have engineered a human adenovirus, ONYX-411, that selectively replicates in human tumor cells, but not normal cells,
depending upon the status of their retinoblastoma tumor suppressor protein (pRB) pathway. Early and late viral gene
expression as well as DNA replication were significantly reduced in a functional pRB-pathway-dependent manner, resulting
in a restricted replication profile similar to that of nonreplicating adenoviruses in normal cells both in vitro and in vivo. In
contrast, the viral life cycle and tumor cell killing activity of ONYX-411 was comparable to that of wild-type adenovirus
following infection of human tumor cells in vitro as well as after systemic administration in tumor-bearing animals.
Introduction Following adenovirus infection, E1A is the first viral gene
product expressed, and is required for efficient transcription of
Human adenoviruses normally infect, propagate, and lyse their all other viral early gene regions (Berk, 1986; Berk et al., 1979;
host cells to release newly generated progeny virus. Although Jones and Shenk, 1979). E1A also promotes S phase entry,
these properties are ideal for killing human cancer cells, virus partly through binding and inactivation of pRB and its related
replication must be restricted to tumor and not normal cells and family members (Bayley and Mymryk, 1994; Howe and Bayley,
tissues. Mutant adenoviruses have now been developed that 1992; Howe et al., 1990; Wang et al., 1991, 1993). The adenovi-
are restricted from efficiently completing their life cycle in normal rus E1B region encodes two major polypeptides, E1B-19K and
cells, but selectively propagate in and lyse tumor cells. In multi- E1B-55K, both of which function to inhibit p53-mediated apo-
ple clinical trials and animal models of human cancer, selectively ptosis of virally infected cells (Debbas and White, 1993; Lowe
replicating adenoviruses have shown varying degrees of antitu- and Ruley, 1993; White, 1995). E1B-55K directly binds to p53
mor efficacy. and represses its transactivation activity (Teodoro and Branton,
Different approaches have been taken to restrict human 1997; Teodoro et al., 1994; Yew and Berk, 1992; Yew et al.,
adenovirus replication in normal cells (Kirn et al., 2001; McCor- 1994), and is required in complex with the adenovirus E4 gene
region product, E4orf6, to target p53 for degradation (Moore etmick, 2001). Originally, the recognition that both tumor cells
and human adenoviruses inactivate the p53 and pRB tumor al., 1996; Nevels et al., 1997; Querido et al., 1997; Steegenga
et al., 1998).suppressor protein functions led to the strategy for engineering
adenoviruses to selectively propagate in human cancer cells Like E1A and E1B, the adenoviral E4 gene region is ex-
pressed early after infection and is an essential component ofbased upon their p53- or pRB-pathway status (Bischoff et al.,
1996; Fueyo et al., 2000). This strategy is based upon the con- the viral life cycle. The E4 gene region encodes several products
whose functions affect the nucleocytoplasmic shuttling of viralcept that the loss of pRB- or p53-pathway functions in tumor
cells should permit replication of E1A or E1B gene mutant vi- RNAs, efficient synthesis and processing of early and late viral
proteins, the induction of apoptosis, and cellular transformation.ruses, respectively (Bischoff et al., 1996; McCormick, 2001).
S I G N I F I C A N C E
Therapeutic agents with enhanced efficacy and strong tumor-cell selectivity are needed to treat human cancers. One novel strategy
is to use selectively replicating human adenoviruses, which amplify and spread throughout the tumor tissue, resulting in direct lysis
of an expanded population of cancer cells. We have engineered ONYX-411 to take advantage of the disruption of the pRB-pathway,
one of the hallmarks of human cancer. Because of its strict dependency upon the functional status of the pRB-pathway, ONYX-411
has a high therapeutic index and is effective as a systemic antitumor agent in animal models of human cancer. In addition, ONYX-
411 gene expression is highly tumor cell selective, making it an ideal delivery vehicle that will express therapeutic transgenes
specifically at the tumor site.
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The E4 gene products function in concert with E1A and E1B to Furthermore, the mechanism used to establish selectivity may
limit their broad utility to treat cancers of different tissue types.create a cellular environment permissive for efficient expression
Here we present a safe and systemically effective humanand processing of viral gene products and ultimately a produc-
adenovirus, ONYX-411, that selectively replicates in a broadtive virus infection.
array of human tumor cell types based upon their defectiveONYX-015 (dl1520), an E1B-55K gene-deleted human ade-
pRB-pathway status. The pRB-pathway is disrupted in nearlynovirus that cannot inactivate p53 (Barker and Berk, 1987), was
all human cancers (Hanahan and Weinberg, 2000; Sherr, 2000),the first therapeutic virus shown to preferentially propagate in
and hence, the oncolytic activity of ONYX-411 is not limited tocancer cells based upon their p53 functional status (Bischoff
tumors of a particular tissue type. ONYX-411 contains a deletionet al., 1996; Ries et al., 2000; Yang et al., 2001). ONYX-015 is
within the E1A-CR2 region, and its pRB-selectivity was furthercurrently in phase III clinical trials in combination with standard
enhanced by replacement of the viral E1A and E4 promoterchemotherapy for the treatment of patients with recurrent can-
regions with the human E2F1 gene promoter. The combinationcers of the head and neck.
of these attributes was essential for selective viral gene expres-pRB plays an essential regulatory role in mediating appro-
sion, viral DNA replication, and tumor cell killing both in vitropriate cellular responses to extracellular stimuli (Bartek et al.,
and in vivo.1997; Larminie et al., 1998; Weinberg, 1995). pRB functions as
a transcriptional repressor to negatively regulate S phase entry
Resultsby directly binding to and repressing the transactivation activity
of the E2F family of transcription factors (Dyson, 1998; Harbour
Construction and characterization of virus mutantsand Dean, 2000). By binding to their promoters, E2Fs regulate
Our goal was to develop a human adenovirus that can selectivelythe expression of a diverse set of genes involved in nucleotide
replicate in human cancer cells based upon disrupted pRB-metabolism, DNA replication, cell cycle control, apoptosis, and
pathway function. In order to generate pRB-pathway selectivity,differentiation (Helin, 1998; Johnson and Schneider-Broussard,
we chose to regulate the expression of the E1A and E4 gene1998; Muller and Helin, 2000). DNA tumor viruses target pRB
products using the pRB-responsive human E2F1 promoter. Thisfamily members, resulting in elevated E2F activity and efficient
promoter was selected because: (1) it is subject to autoregula-S phase entry, the cell cycle phase most permissive for viral
tory control in a cell cycle-dependent manner via four consensusDNA replication and progeny production (Dyson et al., 1989;
E2F DNA binding sites; (2) its activity closely correlates withMoran, 1993). For human adenovirus, two noncontiguous do-
the pRB-pathway status of the cell; (3) the E2F DNA binding
mains of E1A, conserved region 1 (CR1, low affinity) and con-
sequences present within the promoter mediate both repression
served region 2 (CR2, high affinity), are required to mediate pRB
by pRB and stimulation by wild-type, but not CR2 mutants of
binding and inactivation (Dyson et al., 1992; Fattaey et al., 1993). E1A; and (4) it has been used to direct pRB-dependent, tumor-
In concert with E1A function, human adenoviruses further target selective gene expression in vivo, which differentiates between
and direct E2F onto the viral E2 promoter through direct complex normal and aberrant cell cycle states (Johnson et al., 1994;
formation between the E4 gene region product, E4orf6/7, and Neuman et al., 1994; Parr et al., 1997).
E2F (Cress and Nevins, 1994; Helin and Harlow, 1994; Neill et al., To test pRB-responsiveness, we constructed plasmids rep-
1990; Neill and Nevins, 1991; Obert et al., 1994; Raychaudhuri et resenting the left end of the dl922/947 (E1A-CR2) human ade-
al., 1990). novirus genome (Whyte et al., 1989) in which the E1A promoter
Human adenoviruses carrying mutations within the E1A- region was replaced with the previously characterized wild-type
CR2 domain have been tested in the laboratory as potential or mutated alleles of the human E2F1 promoter (Parr et al.,
anticancer agents (Fueyo et al., 2000; Heise et al., 2000). Al- 1997) (Figures 1 and 2). We chose to use the dl922/947 mutation
though these virus mutants can efficiently replicate in both divid- of E1A for our studies since it had been shown that E1A-CR2
ing and nondividing tumor cells, their selectivity in normal cells alleles were not able to overcome pRB-mediated repression of
and safety in animal models has not been demonstrated. An- the E2F DNA binding sequences present within this promoter.
other adenovirus mutant has recently been described that tar- In addition, human adenoviruses carrying mutations within this
gets both the p53 and pRB pathways (Ramachandra et al., E1A domain have previously been tested for their selective repli-
2001). Similarly, the mechanism providing its tumor selectivity cation properties in cancer cells (Fueyo et al., 2000; Heise et
or in vivo utility as a safe and effective systemic anticancer al., 2000). To demonstrate pRB-regulated E1A gene expression,
agent has yet to be demonstrated. C33-A cervical carcinoma cells (pRB mutant) were cotrans-
An alternative approach for developing tumor cell selectivity fected with these constructs along with expression vectors con-
has been the use of tissue- or tumor-specific promoters to taining either wild-type pRB or pRB-Cdk, an allele of pRB
control the expression of the adenovirus early gene regions mutated in all potential CDK phosphorylation sites (Leng et al.,
E1A, E1B, E2, or E4 (Brunori et al., 2001; Doronin et al., 2001; 1997). pRB-Cdk is a constitutively active allele of pRB that is
Fuerer and Iggo, 2002; Hallenbeck et al., 1999; Hernandez- not subject to cell cycle regulation. This allele was used to
Alcoceba et al., 2000; Kurihara et al., 2000; Rodriguez et al., distinguish between direct inactivation of pRB by E1A versus
1997; Yu et al., 1999a, 1999b). By definition, tissue-specific inactivation of pRB by Cdk-mediated phosphorylation as a con-
promoters lack tumor cell selectivity. Another limitation of this sequence of E1A-induced S phase entry. Ectopic expression
approach is that the selected promoter may not be active in all of either pRB or pRB-Cdk resulted in significant repression of
tumor cells derived from the particular tissue type for which it the human E2F1 promoter and E1A expression (Figure 2A, lanes
was chosen. This may be due to heterogeneity in the genetic 2 and 3). Importantly, pRB-mediated repression was dependent
alterations and differentiated state of many tumors, both of upon intact E2F DNA binding sequences, as the promoter con-
struct mutated only in the E2F DNA binding sites was insensitivewhich could influence the activity of tissue-specific promoters.
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Figure 1. Diagram of viruses examined through-
out the course of this study
Mutations specific to each virus are indicated by
the affected region. The presence of a complete
deletion is represented by , whereas the mini-
mal deletion of the E1A-CR2 domain from nucle-
otides 922 to 947 is indicated by CR2. All viruses
were created on an Ad5, dl309 background,
which is characterized by a deletion within the
E3B region that removes the E3-10.4K, 14.5K, and
14.7K immunoregulatory genes. ONYX-015
(dl1520) carries a deletion of the E1B-55K gene,
whereas dl922/47 contains the minimal E1A-CR2
deletion. Unique restriction sites were engi-
neered into the dl922/47 backbone such that
the E1A and/or E4 promoters could be selectively
replaced with the human E2F1 promoter. In the
case of the E1A promoter, HindIII and BamHI sites
were generated at nucleotides 377 and 538, re-
spectively. The E4 promoter was replaced
through the use of newly created XhoI and SpeI
sites at nucleotides 35,576 and 35,815, respec-
tively. Importantly, core enhancer and DNA
packaging elements remained intact at both
ends of the viral genome.
to pRB expression (Figure 2A, lanes 5 and 6). Interestingly, the Viral gene expression, induction of S phase entry,
and viral DNA replicationhighest levels of expression were also observed when E1A was
To examine the link between RB status and viral gene expres-regulated by the wild-type E2F1 promoter (Figure 2A, compare
sion, primary mouse embryonic fibroblasts (MEFs) from isogeni-lane 1 to lanes 4 and 7). This was in accordance with previous
cally matched RB/ and RB/ littermates were infected withobservations regarding the relative strength of the E2F1 pro-
the panel of adenoviruses shown in Figure 1. Regulation ofmoter (Parr et al., 1997). It is important to note that the endoge-
the E1A region (ONYX-150) of human adenovirus by the E2F1nous E1A promoter was also responsive to pRB-Cdk expres-
promoter resulted in a partial repression of E1A protein expres-sion (Figure 2A, lane 9). This may be due to either direct
sion in RB/ but not RB/ MEFs (Figure 3). The most significant
regulation by pRB through the E2F DNA binding sites in the
reduction in E1A expression levels, however, was observed
endogenous E1A promoter or as a consequence of cell cycle when the E2F1 promoter regulated both the E1A and E4 regions
arrest induced by pRB-Cdk expression. (ONYX-411). This reduction in E1A levels was only observed in
These results demonstrated pRB-mediated regulation of the the RB/ and not the RB/ MEFs and was independent of
E2F1 promoter in the context of the adenoviral genome as their proliferation status (Figure 3, lanes 17–21). Interestingly,
measured by E1A expression. We chose to use an E1A-CR2 elevated E1A levels were observed in MEFs infected with ONYX-
allele for our studies since it is possible that any residual wild- 410 (see Discussion). These results indicate that pRB-regulated
type E1A expression could inactivate pRB, thereby circum- E1A gene expression was best achieved with ONYX-411, where
venting regulation of the E2F1 promoter. To demonstrate this the E2F1 promoter controlled both the E1A and E4 gene regions.
possibility, experiments similar to those in Figure 2A were con- E2F activity is deregulated in most human cancers as a
result of pRB-pathway disruption. Regulated expression of theducted, except that an additional plasmid was cotransfected
E1A and E4 gene regions by the E2F1 promoter should, there-that contained either wild-type E1A or E1A-CR2 mutant alleles
fore, be preferentially restricted to human tumor cells and not(dl922/947 or pm928C→G). Expression of exogenous wild-type
normal cells. To test this directly, early and late viral proteinE1A (Figure 2B, lanes 2 and 6), but not E1A-CR2 mutants
expression was measured following infection of a panel of hu-(Figure 2B, lanes 3, 4, 7, and 8), was capable of inactivating
man tumor cell lines and normal proliferating (SAEC-P) or con-pRB- and pRB-Cdk-mediated repression of the E2F1 pro-
tact inhibited (SAEC-CI) primary human lung epithelial cells. Wemoter. Moreover, this inactivation by wild-type E1A was depen-
examined six different tumor cell lines of lung (H1299, H2009,dent upon intact E2F DNA binding sites within the E2F1 pro-
H460, and H2172), pancreatic (MiaPaCa), and breast (MDA-
moter. These results demonstrated that: (1) the E2F1 promoter
MB-231) tissue origin, all of which were defective in their pRB-
was active in the context of the left end of the adenoviral ge- pathway status (Figures 4A–4C and data not shown; see Experi-
nome, and (2) its activity was responsive to pRB-pathway status mental Procedures for the status of pRB-pathway components
only in combination with CR2 mutant alleles and not wild-type in each cell line). E1A protein levels were significantly lower
E1A. Based on these results, we modified the E1A-CR2 mutant in primary human lung epithelial cells (SAEC-P and SAEC-CI)
adenovirus, dl922/947 (Whyte et al., 1989), by replacing viral infected with either ONYX-150 or ONYX-411, where E1A was
regulatory sequences within the E1A (ONYX-150), E4 (ONYX- regulated by the human E2F1 promoter (Figure 4A). This was
410), or both gene regions (ONYX-411) with the human E2F1 in contrast to the E1A levels detected in normal cells following
infection with all of the other viruses where E1A was controlledpromoter (Figure 1).
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of E4orf6/7 detected in tumor cells infected with all viruses
(Figure 4B). We were unable to readily detect E4orf6 expression
in infected tumor cells in these studies. Taken together, the
results in Figures 4A and 4B indicate that E2F1 promoter-regu-
lated transcription of the E1A and E4 viral gene regions resulted
in a significant repression of early viral gene expression in normal
versus tumor cells.
Adenoviral early gene expression is required for induction
of cellular S phase entry, viral DNA replication, and subsequent
expression of late viral messages and capsid proteins. There-
fore, we next examined how each of these steps was affected
in the different E2F1 promoter-regulated viruses. To examine
how viral early gene expression affects the host cell’s division
cycle, we analyzed the cell cycle profile of synchronized, con-
tact-inhibited SAECs following infection with the panel of viruses
used above. Cells were harvested at various times postinfection
and analyzed by flow cytometry to determine the fraction of
cells in the G1, S, or G2/M phases of the cell cycle. As compared
to wild-type virus (dl309) infected cells, a significantly lower
fraction of normal cells infected with ONYX-150, ONYX-410, or
ONYX-411 were in S phase at various times postinfection (Figure
5). In contrast, the fractions of ONYX-015- and dl922/947-
infected cells in S phase were similar to wild-type-infected cells
(Figure 5). As determined by quantitative PCR analysis, the lev-
els of viral DNA replication closely reflected both the time of
entry and fraction of cells in S phase following infection with
each of the viruses (Figure 4C). These studies demonstrate that
ONYX-411 (regulation of both E1A and E4 gene regions by the
E2F1 promoter) was severely attenuated in its ability to induce
S phase entry and to replicate its DNA in normal cells.
Adenovirus late protein expression is dependent upon viral
DNA replication. Therefore, we expected that the attenuated
Figure 2. The human E2F1 promoter is responsive to the status of pRB and replication of the E2F1 promoter-regulated viruses in normal
E1A cells would result in decreased late viral protein expression. As
A: The E1A promoter was either left intact (Ad5) or replaced with the human compared to infected tumor cells, remarkably low levels of the
E2F1 promoter, wild-type (wt) or mutated (mut) in the E2F/DP binding sites, viral capsid proteins hexon (h), penton (p), and fiber (f) were
in a plasmid containing nucleotides 22 to 5,790 of the Ad5 genome. Each
detected in contact inhibited normal lung epithelial cells infectedplasmid carried an additional deletion within the E1A-CR2 domain from
with ONYX-150, ONYX-410, and ONYX-411 (Figure 4C). Al-nucleotides 922 to 947. The promoter-specific plasmids were examined for
pRB-responsiveness by cotransfection assays with a vector expressing wt though at lower than wild-type levels, capsid protein expression
pRB or pRB-Cdk in C33-A cells, a tumor cell line that is deleted for RB1. was observed in proliferating normal cells (SAEC-P, Figure 4C)
Lysates were harvested 48 hr posttransfection and analyzed for pRB and
infected with ONYX-150 and ONYX-410 (E2F1 promoter drivingE1A expression by immunoblotting. B: The same plasmids in A were cotrans-
E1A or E4, respectively). Taken together, these results indicatefected with an additional plasmid that constitutively expressed a truncated
version of E1A that was wt, deleted (dl922/947), or mutated (pm928) within that the combined regulation of the E1A and E4 gene regions
the E1A-CR2 domain. These constitutively expressed forms were truncated (ONYX-411) resulted in the greatest inhibition of both cellular
at their C termini so that they could be distinguished from the reporter, E2F1 and adenoviral DNA replication as well as late viral protein ex-
promoter-driven E1A. Lysates were harvested and analyzed for reporter-
pression in normal human cells, regardless of their proliferativespecific E1A expression as in A. The results are representative of two indepen-
status (Figures 4C and 5, and data not shown).dent experiments.
In vitro and in vivo efficacy of pRB-regulated
adenoviruses
by its endogenous promoter (dl309, dl922/947, ONYX-015, and We next sought to determine the cell killing properties of the
ONYX-410) (Figure 4A). Importantly, E1A expression was at pRB-dependent viruses in infected normal and tumor cells. A
wild-type or enhanced levels in tumor cells infected with all quantitative cell viability assay was used to measure the extent
viruses (Figure 4A). Similar to results obtained after infection of cell killing by each virus (see Experimental Procedures). The
of MEFs, E1A expression was markedly higher and sustained cell lines examined were selected to represent a broad range
following infection of primary human cells with ONYX-410 (see of tumor tissue types including carcinomas of the lung (H1299,
Discussion). Expression of the E4 gene region products, E4orf6 H2009, H460, H522, H520, and A549), colon (SW620), pancreas
and E4orf6/7, was significantly reduced in normal cells infected (MiaPaCa), prostate (DU145), breast (MB231, MB468), cervix
with ONYX-410 and ONYX-411, where E4 transcription was (C33-A), and head and neck (HLaC), as well as osteosarcomas
controlled by the human E2F1 promoter (Figure 4B). This was (U2OS). The normal cells tested also represented a broad range
of primary epithelial cell types, including lung (SAEC, small air-in contrast to the near wild-type expression kinetics and levels
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Figure 3. E2F1 promoter-regulated adenoviruses
are pRB-responsive
Primary mouse embryonic fibroblasts (MEFs) from
isogenically matched RB/ and RB/ littermates
were propagated under proliferating (P) or qui-
escent (Q) growth conditions and infected with
dl922/47, ONYX-150, ONYX-410, or ONYX-411. A
“” sign indicates the alterations specific to
each virus. Cell lysates were generated at vari-
ous hours postinfection (hpi) and examined for
E1A protein expression by immunoblot analysis.
The results are representative of two indepen-
dent experiments.
way; or BEC, bronchial epithelial cells), liver hepatocytes, pros- to day 7, 30% survived to day 12 following ONYX-150 adminis-
tration, and 80% survived to day 7 following ONYX-410 dosing.tate (PrEC), breast (MEC), and kidney (REC), as well as endothe-
lial cells (MVEC, microvascular endothelial cells derived from In contrast, all mice survived when treated at the 2  109 dose
of either dl922/947 or ONYX-411 for the duration of the studyeither lung or dermis). In the panel of tumor cell lines examined,
all of the E2F1 promoter-driven viruses demonstrated a cell (n  10/cohort; data not shown).
At the single i.v. dose of 4  109 pfu, ONYX-411 was thekilling capacity that was comparable to wild-type adenovirus
(Figure 6 and data not shown). In contrast, the E2F1 promoter- only replicating virus that did not result in increased serum AST/
ALT levels on day 3 (Figure 7A). At this dose, no mice surviveddriven viruses were markedly attenuated in their ability to kill all
normal cells tested, independent of the cellular proliferation beyond day 7 when treated with either wild-type or ONYX-
410, and only one of twenty dl922/947-treated animals survivedstatus. ONYX-411’s cytolytic activity in normal cells was compa-
rable to the replication-defective adenovirus, dl312, and was beyond day 7 (Figure 7A). In contrast, the ONYX-411 treated
cohorts demonstrated a delayed toxicity beginning on day 8.approximately 100- to1000-fold lower than wild-type adenovi-
rus, dl309. These results demonstrate that ONYX-411 had the ONYX-411 treated animals did not survive beyond day 12 in
study 1, whereas all of the ONYX-411 treated mice survived togreatest degree of selective cell killing activity.
The systemic delivery of replicating human adenoviruses, day 18 (duration of study) in the second study. Additional studies
demonstrated that the ONYX-411-induced toxicity was alwayseven those modified for tumor-selective replication, has pre-
viously been shown to cause dose-limiting toxicity in mice. This significantly lower in both the time of onset and the number of
affected animals as compared with all other replicating virusestoxicity is associated with liver necrosis and is thought to be a
result of the administered dose of adenoviral coat proteins, viral tested.
Adenovirus preparations often contain a substantial propor-early gene expression, viral replication, and/or de novo late gene
expression. The host immune response may also play a role in tion of defective particles. It is important to note that the lower
toxicities observed with the pRB-regulated viruses were not duemediating this dose-limiting toxicity. To evaluate the safety pro-
file of the E2F1 promoter-driven viruses in vivo, the maximum to the administration of reduced virus particle numbers as the
particle:pfu ratios for all viruses tested were within 0.5- totolerated single dose of each virus was determined following
intravenous (i.v.) administration in Balb/c mice. Survival, weight 8-fold of each other. In fact, more particles per dose were deliv-
ered for all of the pRB-regulated viruses compared to wild-typeloss, and serum levels of the liver enzymes aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) were used virus, dl309 (data not shown). Therefore, we sought to determine
if the reduced toxicity inherent to ONYX-411 correlated withas measures of toxicity following administration of increasing
doses of virus. viral replication and gene expression levels. Livers were har-
vested from mice (n  3) on day 3 following administration ofOne hundred percent survival and no increases in serum
AST/ALT levels were observed in all of the vehicle control and a single i.v. dose of 4  109 pfu and analyzed by quantitative
PCR. The extent of E1A gene expression as well as adenoviralexperimental treatment groups (n  10/cohort) at the 6  108
plaque forming unit (pfu) dose 48 hr (day 3) after virus administra- DNA replication closely mirrored the observed increases in se-
rum AST/ALT levels at equivalent times postinjection for eachtion (Figure 7A). Toxicities were first observed at the 2  109
pfu dose. Weight loss preceded death, which occurred as early of the adenoviruses (compare Figures 7A and 7B, and data
not shown). As compared to wild-type virus (dl309), ONYX-411as day 4 following wild-type (dl309) virus administration. At this
dose, only 40% of the mice treated with wild-type virus survived exhibited the greatest attenuation in viral DNA replication (50-
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Figure 4. E2F1 promoter-driven adenoviruses
demonstrate tumor-selective gene expression in
infected human cells
Human tumor cell lines (MiaPaCa, MB231, H1299)
or primary small airway epithelial cells that were
either proliferating (SAEC-P) or arrested through
contact inhibition (SAEC-CI) were infected with
dl312, dl309, ONYX-015, dl922/47, ONYX-150,
ONYX-410, or ONYX-411. A “” sign indicates the
alterations specific to each virus. At various times
postinfection (T1–T5), cell lysates were gener-
ated and analyzed by immunoblotting for their
early and late gene expression profiles. The hours
postinfection (hpi) represented by T1–T5 were as
follows: MiaPaCa (14, 24, 36, 50, and 64 hpi),
MB231 (12, 25, 36, 47, and 73 hpi), H1299 (12, 25,
37, 48, and 61 hpi), and SAEC-P/-CI (6, 12, 24, 36,
and 48 hpi). A–C: Early gene expression patterns
are demonstrated for E1A (A), E4orf6 (B), and
E4orf6/7 (B). In C, late gene expression patterns
are shown for hexon (h), penton (p), and fiber
(f). In all cases, equal loading was demonstrated
by immunoblot analysis for -actin (data not
shown). In addition, we performed quantitative
PCR analysis to examine adenovirus DNA levels
at 12, 24, 36, and 48 hpi in SAEC-CI cells. Samples
were analyzed in duplicate and are represented
as the fold increase in signal relative to that de-
tected with dl312 at 12 hpi. ND, not determined.
These results are representative of at least two
independent experiments in the primary SAECs
and once in 6 different human tumor cell lines,
three of which are shown.
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Figure 6. Selective tumor cell killing by E2F1 promoter-regulated adenovi-
ruses
Cells were plated at varying densities and infected the following day at
varying MOIs with the indicated viruses. A and B: At selected days postinfec-
tion, cell viability was determined by MTT analysis (see Experimental Proce-
dures). For each tumor cell line and normal cell type, a minimum of two
independent assays was each performed in quadruplicate. A representa-
tive subset of this data is shown for three human, matched tissue types of
tumor (A) and normal (B) cell origin. For lung, 3 non-small cell lung carcino-
mas (H1299, H522, and H520) versus normal proliferating (SAEC-P) and con-
tact inhibited (SAEC-A) small airway epithelial cells are shown. The DU145
prostate carcinoma versus its normal, arrested epithelial cell counterpart,
PrEC-A, is shown. Normal, arrested human hepatocytes were used as a
tissue comparison for the pancreatic carcinoma cell line, MiaPaCa. MOI50
is defined as that MOI which results in 50% cell killing at a particular stopFigure 5. E2F1 promoter-driven adenoviruses are restricted in their ability to
point. The data is presented as the MOI50 for each virus relative to that ofpromote S phase entry
dl309, where low MOI50 ratios are indicative of attenuation. In some instances
Primary human small airway epithelial cells (SAECs) were arrested by pro- (*), the degree of attenuation in cell killing by certain viruses is so great that
longed contact inhibition and infected with the indicated viruses. Cells were the true MOI50 can not be determined. Therefore, in these cases, the extent
collected at various hpi and analyzed by flow cytometry. At a given time of attenuation is actually greater than depicted. ND, not determined.
postinfection, the percentage change in the G1, S, and G2/M phases of
the cell cycle that resulted following infection with each of the replication-
competent adenoviruses is represented relative to the percentage of each
phase following infection with the replication-deficient, dl312 adenovirus
(e.g., % S phase [dl309dl312] at equivalent hpi). These results are represen- had the greatest selectivity index in vitro as well as the best
tative of at least two independent experiments. safety profile in vivo when compared to the other adenoviruses
tested. We next evaluated the systemic antitumor efficacy of
ONYX-411 in nude mice (n  10/cohort) bearing subcutaneous
(s.c.) C33-A human xenograft tumors. A total dose of 2  109
fold) and E1A gene expression (100-fold) in normal mouse pfu was administered intravenously as a daily regimen of 4 
livers in vivo (Figure 7B). The improved safety profile of ONYX- 108 pfu for five consecutive days. Both ONYX-411 and wild-
411 was further demonstrated in primary murine hepatocytes type virus (dl309) demonstrated a significant survival advantage
propagated in vitro, where it was significantly impaired for cell relative to vehicle control (p  0.03 and 0.005, respectively),
killing (10-fold) as well as E1A and late protein expression and resulted in equivalent numbers of complete regressions
when compared to wild-type virus (data not shown). (CRs: n  3/10; Figure 8A). Similar levels of ONYX-411 and
dl309 virus replication were observed in tumor samples by inTaken together, these results demonstrated that ONYX-411
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Figure 7. ONYX-411 results in reduced systemic
toxicity and increased survival following intrave-
nous (i.v.) administration
A: BALB/c mice were injected with a single i.v.
dose of increasing amounts (pfu) of the indi-
cated viruses. On day 3, 48 hpi, mice (n  3)
were analyzed for their serum AST/ALT enzyme
levels. Two independent studies were performed
at the 4  109 dose, with the number of associ-
ated deaths at day 7 indicated. ND, not deter-
mined. B: Livers were harvested on day 3 from
mice (n  3) injected at the 4  109 dose and
analyzed for both adenoviral DNA and E1A-13S
mRNA levels by quantitative PCR analysis. The
resulting signals are represented relative to that
detected with dl312-injected mouse liver sam-
ples (e.g., dl309 DNA signal/dl312 DNA signal).
situ hybridization at 60 and 66 days posttreatment, respectively hope of developing novel cancer therapeutic agents. These
include small molecule inhibitors of Cdk4 kinase enzyme, deliv-(Figure 8B). In two independent studies using the C33-A cervical
cancer xenograft model, increasing the dose of ONYX-411 by ery of p16INK4a or RB1 genes, inhibitors of E2F DNA binding
or dimerization, and various antisense approaches targetingapproximately 2-fold (3.75 109 pfu total, administered as 7.5
108 pfu on days 1–5) resulted in a comparable survival advantage activated components of the pRB-pathway (Garrett and Fattaey,
1999; Rao, 1996). Genetically engineered herpes simplex virusat day 70 (range: 60%–70% of mice) without increased toxicity
(Figure 8A). In these studies, cure rates ranged from 25%–60% mutants have also been designed to target alterations within the
pRB-pathway, thereby promoting an enhanced tumor-restricted(Figure 8A). Subsequent studies have also demonstrated that
ONYX-411 can be administered systemically in tumor bearing, replication profile (Chase et al., 1998; Chung et al., 1999; Kramm
et al., 1997; Mineta et al., 1994, 1995; Nakamura et al., 2001).immunocompromised mice (Balb/c genetic background) at
doses up to a total of 5  109 pfu (1  109 pfu administered We have developed ONYX-411 as a novel cancer therapeutic
agent based upon the known functions of the viral early geneon days 1–5) with no increased toxicity. This dose is 2-fold
higher than the previously reported tolerated dose for ONYX- products during the adenovirus life cycle and their complex
interactions with the pRB tumor suppressor pathway. ONYX-015 (Heise et al., 1999) (data not shown).
411 is based upon the dl922/947 human adenovirus that con-
tains a 24 base pair deletion in the conserved region 2 of E1ADiscussion
(Whyte et al., 1989). In addition, expression of the viral E1A and
E4 gene regions was brought under the control of the cellularThe pRB-pathway is disrupted in nearly all human cancers (Ha-
nahan and Weinberg, 2000; Sherr, 2000). A number of strategies E2F1 promoter. We have demonstrated that the combination
of these features in ONYX-411 was crucial for selective viralhave been employed to target defects in this pathway in the
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Figure 8. Tumor efficacy and evidence of viral replication following i.v. administration of ONYX-411 in mice bearing C33-A human tumor xenografts
A: Mice (n  8 or 10) were treated with an i.v. injection dose of vehicle control (PBS) or either 2  109 pfu or 3.75  109 pfu of the indicated viruses
administered as a daily regimen of 4  108 or 7.5  108 pfu, respectively, for five consecutive days on days 1 through 5 of the study. The cumulative fraction
of mice surviving over time is plotted. The observed number of complete responses for each cohort is indicated in the legend immediately following the
daily dose. The three ONYX-411 cohorts were from three independent studies; those viruses above the dotted line were all done within the same study,
whereas the two cohorts of ONYX-411 below the dotted line were from two separate studies. B: Tumors were isolated from mice dosed at 2  109 pfu in
A on day 71 (dl312 and dl309) and day 65 (ONYX-411) of the study and examined for the presence of newly replicated adenoviral DNA by in situ
hybridization. Virally infected tumor cells (dark blue stain; black arrow) are evident throughout the sections from mice infected with either dl309 or ONYX-411.
gene expression, replication, and progeny production in tumor contained an inactivating mutation within the E4orf6/7 gene
product, but we did not observe an increase in its relative tumorbut not normal human cells. This resulted in the selective killing
of tumor cells in vitro, reduced in vivo systemic toxicity, and a versus normal cell killing selectivity (data not shown). Therefore,
modulating the expression of the E4 gene region by the humansurvival benefit in animal models of human cancer following
systemic administration. E2F1 promoter appears to be sufficient to regulate these func-
tions of E4orf6/7.E1A-CR2 mutant adenoviruses have previously been
shown to possess antitumor activity in culture and in in vivo Interestingly, we detected enhanced E1A protein levels fol-
lowing infection of either normal human or mouse cells withmodels of human cancer (Fueyo et al., 2000; Heise et al., 2000).
Although our results are consistent with previous observations ONYX-410 (E1A-CR2, E2F1 promoter controlling E4). This
upregulation in E1A protein levels may be attributed to the re-that E1A-CR2 adenoviruses replicate efficiently in human tu-
mor cells, we have not observed the level of selectivity with duced E4 gene expression resulting from E2F1 promoter regula-
tion. One candidate E4 gene product mediating this effect maythese viruses that is required for them to be considered tumor-
specific and safe cancer therapeutic agents. This may partly be be E4orf4, which has previously been shown to modulate E1A
function (and possibly levels) through its interactions with theexplained by the fact that while E1A-CR2 mutant adenoviruses
are compromised in their ability to inactivate pRB, they are still protein phosphatase, PP-2A (Kleinberger and Shenk, 1993;
Muller et al., 1992; Whalen et al., 1997). Alternatively, E4orf6capable of mediating S phase entry via their intact CR1 domain
(Howe et al., 1990; Wang et al., 1991, 1993). Furthermore, both and possibly E4orf6/7, which play novel roles in downregulating
E1A protein levels (L.J., F.M., and C. O’Shea, unpublished data),early and late viral gene expression remain intact following infec-
tion with these viruses, even in normal human cells (see Figures may also contribute to this phenotype.
We closely examined the virus life cycle in normal human4A–4C).
We have shown that regulation of both the E1A and the E4 cells following infection with the E2F1 promoter-driven adeno-
viruses reported in this study. Based upon our results withgene regions by the human E2F1 promoter is necessary to
achieve pRB-pathway selectivity for replication and late viral ONYX-150 and ONYX-411, it is clear that in order to mediate
efficient S phase entry and viral DNA replication, the onset andgene expression. Although not tested in the context of the full
viral genome in this study, we provide evidence that expression expression of E1A must be near wild-type levels. In addition,
as evident from cells infected with ONYX-410 and ONYX-411,of wild-type E1A is able to overcome the pRB-regulated nature
of the E2F1 promoter inserted in the left end of the adenovirus robust E4 gene expression is also required for efficient viral
DNA replication. Therefore, we conclude that the life cycle ofgenome. This indicates that the selectivity provided by the E2F1
promoter for controlling viral gene expression can only be the pRB-regulated viruses, and in particular ONYX-411, is halted
prior to viral DNA replication in normal human cells. It shouldachieved in combination with mutations in the E1A-CR2 region.
In addition to E1A, the E4orf6/7 gene product is known to inde- also be noted that while it is positively regulated by E1A, tran-
scription of the E4 gene region can occur in an E1A-independentpendently enhance E2F activity on the adenovirus E2 promoter
(Helin and Harlow, 1994; Neill et al., 1990; Neill and Nevins, manner. This is evident from E4 gene expression at a time when
E1A protein was not detectable in ONYX-150 infected normal1991; O’Connor and Hearing, 1994; Obert et al., 1994; Ray-
chaudhuri et al., 1990; Reichel et al., 1989) as well as the cellular, human cells (Figure 4B).
ONYX-015 (dl1520) was the first adenovirus developedhuman E2F1 promoter (Schaley et al., 2000). To this end, we
have generated and examined an ONYX-411 virus that also based upon its ability to selectively replicate in human cancers
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and has shown great promise in late-phase clinical trials (Khuri Hawkins et al., 2001). Examination of ONYX-411’s utilities for
these strategies is currently underway.et al., 2000; Kirn, 2001; Nemunaitis et al., 2000, 2001a, 2001b).
ONYX-015 replication is rendered p53-pathway selective by
Experimental proceduresvirtue of a deletion of the E1B-55K gene (Barker and Berk, 1987;
Bischoff et al., 1996; Ries et al., 2000; Yang et al., 2001). In
Transient transfections
complex with E4orf6, E1B-55K not only mediates p53 degrada- C33-A cells were seeded into 10 cm dishes. The next day, 5 g each of
tion, but also plays an important role in regulating the nucleocy- a promoter-specific reporter plasmid (pXC1.SV-922/947, pWT.E2F1P-922/
toplasmic shuttling of late viral messages and shutoff of host 947, or pMUT.E2F1P-922/947), a pRB expression plasmid (pCMV.Neo-
Bam, pCMV.RB, or pCMV.RBcdk), and an E1A-ER expression plas-cell protein synthesis. Thus, deletion of the entire E1B-55K gene
mid (pCAN.myc1-ER, pCAN.E1A.WT-ER, pCAN.E1A.922/947-ER, orin ONYX-015 may contribute to its attenuated replication in
pCAN.E1A.928-ER) were mixed together with 10 g of pGEM plasmid DNAsome human cancer cell lines. In this respect, adenovirus mu-
(25 g total DNA) and 250 mM CaCl2. The DNA/CaCl2 solution was thentants have recently been generated that specifically target E1B-
added dropwise, with constant bubbling, to an equal volume of 2 HBS
55K’s p53 binding function while preserving its role(s) late in (pH 7.25) and incubated for 25 min at RT. The DNA precipitate was then
the viral life cycle (Shen et al., 2001). In cell culture studies, added slowly to the cells and left O/N at 37	C/5% CO2. Transfections were
stopped by washing the cell monolayer 2 with PBS/10% FBS, followedthese viruses demonstrated an improved replication capacity
by replacement with growth medium supplemented with 10% FBS and 1compared to that of ONYX-015. Similarly, in our in vitro studies,
M tamoxifin. Cells were harvested 48 hr posttransfection and lysates pre-ONYX-411 demonstrated a higher cell killing capacity than
pared as described below.ONYX-015 in nearly all cell lines examined.
A number of studies have previously characterized an inher- Flow cytometry analysis
ent toxicity following intravenous administration of human ade- Cells were washed 1 with PBS, harvested by trypsinization at 37	C for 5
noviruses in mice (Duncan et al., 1978; Engelhardt et al., 1994; min, neutralized in medium containing 10% FBS, and aggregates dispersed
through repeated pipetting. Cells were then pelleted at 1,500 rpm, 4	C forHeise et al., 1999; Yang et al., 1994). Increased serum levels
5 min, washed 1 with cold PBS/1% FBS and then 1 with cold PBS. Cellof the liver enzymes AST and ALT, degeneration of liver tissue,
pellets were thoroughly resuspended in 200 l of cold PBS and fixed O/Nand severe weight loss often accompany these toxicities. Al-
at 4	C following the slow addition of 3 mls of 70% EtOH/15 mM glycine (pHthough the underlying mechanisms responsible for the lower
2.8) while vortexing. Fixed cells were pelleted as before and washed 1
systemic toxicity associated with ONYX-411 are not clearly re- with cold PBS/1% FBS. Cell pellets were then resuspended in 500 l of 1
solved, the combination of all three features built into this virus PI buffer (PBS, 1% FBS, 250 g/ml RNase A, and 15 M propidium iodide),
incubated for 30 min at 37	C, and either analyzed immediately or stored atcontribute to this phenotype. dl922/947 (E1A-CR2), ONYX-
4	C in the dark for up to 24 hr. Samples were passed through a filter cap150 (E1A-CR2, E2F1 promoter controlling E1A), and ONYX-
immediately prior to analysis on a FACSCaliburTM, and data was analyzed410 (E1A-CR2, E2F1 promoter controlling E4) all demonstrated
either using ModFit or CellQuest.significantly higher levels of E1A gene expression, DNA replica-
tion, and ensuing systemic toxicity than was observed with Supplemental data
ONYX-411. It is likely, therefore, that either E1A, certain E4 gene Additional experimental procedures can be found as supplemental data at
products, or the coincident expression of these gene products http://www.cancercell.org/cgi/content/full/1/4/325/DC1.
in infected mouse liver tissue contributes to the hepatic toxicity
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